美罗培南配合免疫球蛋白治疗新生儿败血症的疗效及其对炎症因子的影响

Efficacy of meropenem combined with immunoglobulin in the treatment of neonatal sepsis and its effect on inflammatory factors

摘要:

目的?探讨新生儿败血症患儿实施美罗培南配合免疫球蛋白治疗的疗效及炎症水平变化。方法?选取2016年4月—2018年4月海南医学院第二附属医院收治的新生儿败血症患儿100例，以挂号就诊单病案号单、双数为基准，分为研究组和对照组。治疗组采用美罗培南+免疫球蛋白治疗，对照组采用美罗培南治疗，对比两组临床症状改善时间、临床疗效、炎症水平及临床指标。结果?研究组拒奶改善时间、体温改善时间、神经系统症状改善时间、血培养转阴时间及住院时间低于对照组（P?<0.05），研究组总有效率高于对照组（P?<0.05），研究组治疗前后白细胞介素-6、白细胞介素-1、高敏感C反应蛋白及肿瘤坏死因子-α的差值高于对照组（P?<0.05），研究组治疗前后分化抗原3、分化抗原8、免疫球蛋白G及免疫球蛋白M的差值高于对照组（P?<0.05）。结论?新生儿败血症患儿实施美罗培南配合免疫球蛋白治疗的临床疗效显著，可明显改善机体炎症水平，值得借鉴。

Abstract:

Objective To investigate the clinical efficacy of meropenem combined with immunoglobulin in the treatment of neonatal sepsis and its effects on the levels of inflammatory factors.?Methods?One hundred patients with neonatal sepsis admitted to our hospital from April 2016 to April 2018 were enrolled in the study and were divided into study group (50 cases) and control group (50 cases). The study group was given meropenem and immunoglobulin, while the control group only received meropenem. The time needed for clinical symptoms improvement, clinical efficacy, inflammation level, and other relevant clinical indicators were compared between the two groups.?Results?The time needed for clinical symptoms improvement of the study group was lower than that of the control group (P < 0.05). The overall clinical efficacy of the study group was higher than that of the control group (P < 0.05). The inflammation level of the study group was lower than that of the control group (P?